Regeneron Pharmaceuticals (REGN)$638.88
Market Cap: 65.17 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Regeneron Pharmaceuticals (REGN).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
15.2x
EV/FCF, 6.6% FCF yield
Quality
14.4%
ROIC, 28.4% FCF margin
Growth
11.0%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 4.1x current ratio
Superinvestors
3
Top: Mason Hawkins (5.0%)
Strengths to research
- Revenue compounded at 11.0% over five years.
- Free cash flow compounded at 15.3% over five years.
- Free cash flow margin is healthy at 28.4%.
- Debt/equity looks manageable at 0.0x.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for REGN.
Grade B
67
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| REGN Target | Regeneron Pharmaceuticals | $65.2B | 15.4x | 15.2x | 14.4% | 11.0% | 28.4% | N/A | -0.8x | N/A |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 127.7x | 72.5x | 39.8% | 49.8% | 12.5% | N/A | -3.0x | N/A |
| BNTX | Biontech Se ADR | $24.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RPRX | Royalty Pharma plc | $19.0B | 30.6x | 11.0x | 4.1% | 2.3% | 104.7% | N/A | 5.3x | N/A |
| INCY | Incyte Corp. | $12.0B | 15.2x | 6.3x | 24.9% | 14.0% | 27.5% | N/A | -1.9x | N/A |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
| MRNA | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
Financial Charts
No financial data available for REGN (annual).
3 superinvestors own REGN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 4,458,238 | $3.4B | 1.89% | 0.0% |
| Harry Burn Sound Shore | 150,960 | $117M | 3.91% | 0.0% |
| Mason Hawkins Longleaf Partners | 130,662 | $101M | 4.97% | 0.0% |